DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience.

Dexcom is transforming its Stelo CGM into a whole-family wellness device, securing FDA clearance for pediatric use and debuting new AI tools.

Ultrahuman has expanded its digital health ecosystem with the US launch of M2 Live, an updated metabolic health platform that integrates continuous glucose data from Abbott’s over-the-counter Lingo ...

Samsung Galaxy Watch blood sugar tracking is still a rumor, not reality. Here’s the timeline, research, current options, and ...

Apple Watch blood sugar tracking remains unconfirmed. Here's the latest on the timeline, patents, technical challenges, and what Apple Watch can do now.

On a promising note, management expects CGM to return to double-digit growth in the second quarter. The Libre portfolio, Abbott’s flagship CGM franchise, is used by more than 8 million people across ...

June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom (DXCM.O), opens new tab glucose sensors it bought from licensed distributors had been ‌slated for destruction, after ...

Add Yahoo as a preferred source to see more of our stories on Google. June 11 (Reuters) - Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose ‌sensors it bought from licensed ...